Cwm LLC Has $173,000 Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Cwm LLC grew its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 69.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,870 shares of the biotechnology company’s stock after buying an additional 765 shares during the quarter. Cwm LLC’s holdings in Blueprint Medicines were worth $173,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Blueprint Medicines by 3.2% during the 1st quarter. Vanguard Group Inc. now owns 6,309,977 shares of the biotechnology company’s stock valued at $598,564,000 after purchasing an additional 195,007 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Blueprint Medicines by 15.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,250,823 shares of the biotechnology company’s stock valued at $592,954,000 after buying an additional 821,868 shares during the last quarter. American Century Companies Inc. grew its holdings in Blueprint Medicines by 4.2% during the second quarter. American Century Companies Inc. now owns 802,733 shares of the biotechnology company’s stock worth $86,519,000 after buying an additional 32,600 shares in the last quarter. Millennium Management LLC raised its position in Blueprint Medicines by 540.0% in the 2nd quarter. Millennium Management LLC now owns 627,626 shares of the biotechnology company’s stock valued at $67,646,000 after buying an additional 529,566 shares during the last quarter. Finally, Hood River Capital Management LLC lifted its stake in Blueprint Medicines by 7.0% during the 2nd quarter. Hood River Capital Management LLC now owns 502,820 shares of the biotechnology company’s stock valued at $54,194,000 after acquiring an additional 32,694 shares in the last quarter.

Insider Activity at Blueprint Medicines

In other Blueprint Medicines news, insider Philina Lee sold 41,913 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $93.19, for a total value of $3,905,872.47. Following the completion of the sale, the insider now owns 34,729 shares of the company’s stock, valued at $3,236,395.51. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Philina Lee sold 41,913 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the completion of the sale, the insider now directly owns 34,729 shares in the company, valued at approximately $3,236,395.51. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Fouad Namouni sold 3,633 shares of Blueprint Medicines stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the sale, the insider now owns 69,070 shares in the company, valued at approximately $6,169,332.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.21% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

BPMC has been the subject of several recent analyst reports. Oppenheimer upped their target price on shares of Blueprint Medicines from $114.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday, July 8th. Needham & Company LLC reiterated a “buy” rating and issued a $130.00 price objective on shares of Blueprint Medicines in a research note on Thursday, August 1st. Morgan Stanley boosted their target price on Blueprint Medicines from $110.00 to $115.00 and gave the stock an “equal weight” rating in a research note on Friday, July 12th. Guggenheim increased their price target on Blueprint Medicines from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Finally, Robert W. Baird boosted their price objective on Blueprint Medicines from $112.00 to $127.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Blueprint Medicines presently has a consensus rating of “Moderate Buy” and a consensus price target of $120.00.

Blueprint Medicines Price Performance

Shares of NASDAQ BPMC opened at $84.40 on Thursday. Blueprint Medicines Co. has a fifty-two week low of $43.89 and a fifty-two week high of $121.90. The stock has a fifty day moving average of $90.20 and a 200-day moving average of $98.76. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.65 and a current ratio of 3.71. The stock has a market cap of $5.28 billion, a PE ratio of -17.98 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.49. The firm had revenue of $138.20 million during the quarter, compared to analyst estimates of $104.02 million. Blueprint Medicines had a negative net margin of 56.64% and a negative return on equity of 157.30%. The business’s revenue for the quarter was up 139.9% on a year-over-year basis. During the same period in the previous year, the business earned ($2.19) EPS. Equities research analysts anticipate that Blueprint Medicines Co. will post -3.99 earnings per share for the current year.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.